preclinical trial


Also found in: Dictionary, Wikipedia.
Related to preclinical trial: preclinical study
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for preclinical trial

a laboratory test of a new drug or a new invasive medical device on animal subjects

References in periodicals archive ?
In light of the positive results of the preclinical trial, Kadimastem intends to conduct preliminary talks (prc-IND) with regulatory authorities such as the FDA to pave the regulatory path to conducting clinical trials.
The company is simultaneously conducting several clinical and preclinical trials with the two drugs for various indications.
Tokyo, Japan, June 16, 2006 - (JCN) - Kaneka has obtained positive results from preclinical trials for a drug eluting stent (DES) that it is currently developing.
We want to ensure (that) the same safety level we achieved in preclinical trials with mice and other animals can be achieved with humans,'' said David Kaye, spokesman at the Thousand Oaks-based company.
Additional pipeline programs in HIV maturation inhibition and HIV fusion inhibition are currently being tested in preclinical trials.
The new compound, which is currently in preclinical trials in Japan, has a property that inhibits the activity of MAPK/ ERK kinase (MEK), a kind of enzyme involved in cell proliferation.
Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of NeuroVax[TM] or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that NeuroVax[TM] or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of NeuroVax[TM] or IR103 in preclinical trials and/or earlier clinical trials.
Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of NeuroVax [TM] or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that NeuroVax[TM] or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of NeuroVax[TM] or IR103 in preclinical trials and/or earlier clinical trials.
Preclinical trials conducted by the company have shown that CF102 performs well in the inhibition of liver cancer in animal models.
Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of NeuroVax(TM)or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that NeuroVax(TM)or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of NeuroVax(TM)or IR103 in preclinical trials and/or earlier clinical trials.
Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of NeuroVax(TM) or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that NeuroVax(TM) or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical trials.